Bielsa I, Ariza A. Deep morphea. Semin Cutan Med Surg. 2007;26
(2):90–95.
Dańczak-Pazdrowska A, Cieplewicz P, Żaba R, et al. Controversy around the morphea. Postepy Dermatol Alergol. 2021;38(5):
716–720.
Fett N, Werth VP. Update on morphea: part I. Epidemiology,
clinical presentation, and pathogenesis. J Am Acad Dermatol.
2011;64(2):217–228...
Zulian F, Athreya BH, Laxer R, et al. Juvenile scleroderma
working Group of the Pediatric Rheumatology European
Society (PRES). Juvenile localized...
Fett N, Werth VP. Update on morphea: part II. Outcome
measures and treatment. J Am Acad Dermatol. 2011;64(2):
231–242.
Kreuter A, Krieg T, Worm M, et al. German guidelines for the
diagnosis and therapy of localized scleroderma. J Dtsch
Dermatol Ges. 2016;14(2):199–216.
Zulian F, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis....
Leitenberger JJ, Cayce RL, Haley RW, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and
pediatric cases. Arch Dermatol....
Saracino AM, Denton CP, Orteu CH. The molecular pathogenesis of morphoea: from genetics to future treatment targets. Br
J Dermatol. 2017;177(1):34–46.
Abbas L, Joseph A, Kunzler E, et al. Morphea: progress to date
and the road ahead. Ann Transl Med. 2021;9(5):437.
O’Brien JC, Rainwater YB, Malviya N, et al. Transcriptional
and cytokine profiles identify CXCL9 as a biomarker of
disease activity in morphea....
Mertens JS, de Jong EMGJ, Pandit A, et al. Regarding “Transcriptional and cytokine profiles identify CXCL9 as a biomarker of disease activity...
Mirizio E, Marathi A, Hershey N, et al. Identifying the signature
immune phenotypes present in pediatric localized scleroderma. J Invest Dermatol....
Damsky W, Patel D, Garelli CJ, et al. Jak Inhibition prevents
bleomycin-induced fibrosis in mice and is effective in patients
with morphea....
Smith V, Piette Y, van Praet JT, et al. Two-year results of an
open pilot study of a 2-treatment course with rituximab in
patients with early...
Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of
rituximab in systemic sclerosis (DESIRES): a double-blind,
investigator-initiated,...
Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of
rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind,...
Gordon JK, Martyanov V, Franks JM, et al. Belimumab for the
treatment of early diffuse systemic sclerosis: results of a
randomized, double-blind,...
Adeeb F, Anjum S, Hodnett P, et al. Early- and late-stage
morphea subtypes with deep tissue involvement is treatable
with Abatacept (Orencia)....
Kalampokis I, Yi BY, Smidt AC. Abatacept in the treatment of
localized scleroderma: a pediatric case series and systematic
literature review....
Fage SW, Arvesen KB, Olesen AB. Abatacept improves skinscore and reduces lesions in patients with Llocalized scleroderma: a case series. Acta...
Li SC, Torok KS, Ishaq SS, et al. Preliminary evidence on
abatacept safety and efficacy in refractory juvenile localized
scleroderma. Rheumatology...
Khanna D, Spino C, Johnson S, et al. Abatacept in early diffuse
cutaneous systemic sclerosis: results of a phase II investigator-initiated,...
Kim SR, Charos A, Damsky W, et al. Treatment of generalized
deep morphea and eosinophilic fasciitis with the Janus kinase
inhibitor tofacitinib....
Liu L, Zhan Y, Shi Y, et al. Bullous lichen sclerosus-generalized
morphea overlap syndrome improved by tofacitinib. Dermatol
Ther. 2022;35(12):e15942.
Tang JC, Zheng WY, Han GM, et al. Successful treatment of
paediatric morphea with tofacitinib. Acta Derm Venereol. 2023;
103 adv4805.
Scheinberg M, Sabbagh C, Ferreira S, et al. Full histological and
clinical regression of morphea with tofacitinib. Clin Rheumatol.
2020;39(9):2827–2828.
McGaugh S, Kallis P, De Benedetto A, et al. Janus kinase
inhibitors for treatment of morphea and systemic sclerosis: a
literature review....
Labrandero Hoyos C, Peñuelas Leal R, Echevarría AG, et al.
JAK-STAT pathway is involved in cutaneous sclerosis processes: Generalized morphea...
Zou Q, Wei R, Yao Z, et al. Successful treatment with
baricitinib of linear morphea following the lines of Blaschko
mimicking lichen striatus....
Khanna D, Padilla C, Tsoi LC, et al. Tofacitinib blocks IFNregulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis...
Negrini S, Spanò F, Penza E, et al. Efficacy of cilostazol for the
treatment of Raynaud’s phenomenon in systemic sclerosis
patients. Clin...
Kassamali B, Elman SA, Sheets AR, et al. A case of paradoxical
fibrosis and development of morphea in a patient on
dupilumab. JAAD Case Rep....
Lythgoe H, Baildam E, Beresford MW, et al. Tocilizumab as a
potential therapeutic option for children with severe, refractory juvenile localized...
Zhang A, Nocton J, Chiu Y. A Case of pansclerotic morphea
treated with tocilizumab. JAMA Dermatol. 2019;155(3):388–389.
Cardoneanu A, Burlui AM, Macovei LA, et al. Targeting
systemic sclerosis from pathogenic mechanisms to clinical
manifestations: why IL-6?...
Martini G, Campus S, Raffeiner B, et al. Tocilizumab in two
children with pansclerotic morphoea: a hopeful therapy for
refractory cases? Clin...
Coelho-Macias V, Mendes-Bastos P, Assis-Pacheco F, et al.
Imatinib: a novel treatment approach for generalized
morphea. Int J Dermatol. 2014;53(10):1299–1302.
de Masson A, Bouaziz JD, Peffault de Latour R, et al. Limited
efficacy and tolerance of imatinib mesylate in steroidrefractory sclerodermatous...
Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses
connective tissue growth factor production in fibroblasts and
in the skin of scleroderma...
Richeldi L, Fernández Pérez ER, Costabel U, et al.
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary...
DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical
features and pathogenesis. J Am Acad Dermatol. 2020;82(2):
267–281.
Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis
and treatment. J Am Acad Dermatol. 2020;82(2):283–296.
Galimberti F, Li Y, Fernandez AP. Clinically amyopathic
dermatomyositis: clinical features, response to medications
and malignancy-associated...
Callander J, Robson Y, Ingram J, et al. Treatment of clinically
amyopathic dermatomyositis in adults: a systematic review.
Br J Dermatol....
Piguet V, Choy E. Dermatomyositis: a slow path towards
targeted therapies or will conventional therapies prevail? Br J
Dermatol. 2018;179(6):1233–1234.
Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with...
Wolstencroft PW, Casciola-Rosen L, Fiorentino DF. Association between autoantibody phenotype and cutaneous adverse
reactions to hydroxychloroquine...
Hayashi M, Kikuchi T, Takada T. Mycophenolate mofetil for
the patients with interstitial lung diseases in amyopathic
dermatomyositis with...
Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for
management of polymyositis and dermatomyositis among
rheumatologists, neurologists...
Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev
Rheumatol. 2018;14(5):279–289 Erratum in: Nat Rev Rheumatol.
2018; 14(10): 619.
Ahmed S, Chen KL, Werth VP. The validity and utility of the
cutaneous disease area and severity index (CDASI) as a
clinical outcome instrument...
Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of
intravenous immune globulin in dermatomyositis. N Engl J
Med. 2022;387(14):1264–1278.
Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the
treatment of refractory adult and juvenile dermatomyositis
and adult polymyositis:...
Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous
improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab....
Tjärnlund A, Tang Q, Wick C, et al. Abatacept in the treatment
of adult dermatomyositis and polymyositis: a randomised,
phase IIb treatment...
Curiel RV, Nguyen W, Mamyrova G, et al. Improvement in
disease activity in refractory juvenile dermatomyositis following abatacept therapy....
Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib citrate for
refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol....
Min MS, Alsarheed A, Kassamali B, et al. Tofacitinib as
treatment for refractory dermatomyositis: a retrospective
study from 2 academic medical...
Wendel S, Venhoff N, Frye BC, et al. Successful treatment of
extensive calcifications and acute pulmonary involvement in
dermatomyositis with...
Sözeri B, Demir F. A striking treatment option for recalcitrant
calcinosis in juvenile dermatomyositis: tofacitinib citrate.
Rheumatology...
Ohmura SI, Yamabe T, Naniwa T. Successful dose escalation
of tofacitinib for refractory dermatomyositis and interstitial
lung disease with...
Zhang J, Sun L, Shi X, et al. Janus kinase inhibitor, tofacitinib,
in refractory juvenile dermatomyositis: a retrospective multicentral study...
Hornung T, Janzen V, Heidgen FJ, et al. Remission of
recalcitrant dermatomyositis treated with ruxolitinib. N Engl J
Med. 2014;371(26):2537–2538.
Delvino P, Bartoletti A, Monti S, et al. Successful treatment
with baricitinib in a patient with refractory cutaneous
dermatomyositis. Rheumatology...
Kim H, Dill S, O’Brien M, et al. Janus kinase (JAK) inhibition
with baricitinib in refractory juvenile dermatomyositis. Ann
Rheum Dis. 2021;80(3):406–408.
Beckett M, Dutz J, Huang K. Upadacitinib therapy in refractory
inflammatory myositis: a case series of 10 patients. RMD Open.
2024;10(1):e003837.
Le Voyer T, Gitiaux C, Authier FJ, et al. JAK inhibitors are
effective in a subset of patients with juvenile dermatomyositis: a monocentric...
Bitar C, Maghfour J, Ho-Pham H, et al. Apremilast as a
potential treatment for moderate to severe dermatomyositis:
a retrospective study of...
Qiblawi SH, Fivenson DP. Apremilast as an adjuvant therapy
for calcinosis cutis. JAAD Case Rep. 2019;5(10):874–876.
Charlton D, Moghadam-Kia S, Smith K, et al. Refractory
cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast. J Clin...
Konishi R, Tanaka R, Inoue S, et al. Evaluation of apremilast,
an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis:...
